[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336665-105":59,"doc-detail-336665-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","reshaping-the-tumor-immune-microenvironment-to-improve-car-t-cell-based-cancer-immunotherapy","Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","","Adoptive transfer of chimeric antigen receptor (CAR) T cells has shown strong results in hematologic malignancies, yet solid-tumor efficacy remains limited. Tumor immunosuppressive microenvironments restrict CAR-T effectiveness and safety, making strategies to enhance CAR-T infiltration and counter local immunosuppressive signaling critical. The review highlights approaches such as structurally modifying CAR-T cells and combining them with targeted therapy, radiotherapy, or chemotherapy. It also emphasizes monitoring the tumor microenvironment and CAR-T status to evaluate strategy viability and accelerate progress.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reshaping-the-tumor-immune-microenvironment-to-improve-car-t-cell-based-cancer-immunotherapy/336665/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reshaping-the-tumor-immune-microenvironment-to-improve-car-t-cell-based-cancer-immunotherapy/336665.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are current CAR-T therapies less effective for solid tumors?","Question",{"text":113,"@type":114},"Solid tumors often contain an immunosuppressive tumor microenvironment that limits CAR-T effectiveness and safety, reducing infiltration and function.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What strategies are suggested to improve CAR-T cell performance in tumors?",{"text":118,"@type":114},"The review emphasizes enhancing CAR-T infiltration and resolving immunosuppressive responses, including structural CAR-T alterations combined with targeted therapy, radiotherapy, or chemotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the tumor microenvironment contribute to CAR-T exhaustion?",{"text":122,"@type":114},"Physical and cytokine barriers, along with immunosuppressive molecules and cells, can create metabolic competition, depriving CAR-T cells of energy and promoting exhaustion.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336665,1790106262,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Xia et al. Molecular Cancer (2024) 23:175 [https://doi.org/10.1186/s12943-024-02079-8](https://doi.org/10.1186/s12943-024-02079-8)  \nMolecular Cancer  \nREVIEW Open Access  \nReshaping the tumor immune microenvironment to improve CAR-T cellbased cancer immunotherapy  \nXueting Xia 1†, Zongxin Yang 1†, Qisi Lu2,5†, Zhenyun Liu3, Lei Wang3, Jinwen Du3, Yuhua Li3*, Dong-Hua Yang4* and Shaojie Wu3*  \nAbstract  \nIn many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment efficacy. Current CAR-T therapies are particularly discouraging for solid tumor treatment. The immunosuppressive microenvironment of tumors affects CAR-T cells, limiting the treatment’s effectiveness and safety. Therefore, enhancing CAR-T cell infiltration capacity and resolving the immunosuppressive responses within the tumor microenvironment could boost the anti-tumor effect. Specific strategies include structurally altering CAR-T cells combined with targeted therapy, radiotherapy, or chemotherapy. Overall, monitoring the tumor microenvironment and the status of CAR-T cells is beneficial in further investigating the viability of such strategies and advancing CAR-T cell therapy.  \nKeywords CAR-T, Tumor microenvironment, Tumor immunotherapy, Solid tumor  \n†Xueting Xia, Zongxin Yang and Qisi Lu contributed equally to this work.  \n*Correspondence: Yuhua Li  \nliyuhua201 [1gz@163.com](1gz@163.com)  \nDong-Hua Yang [dong-hua.yang@nyctcm.edu](dong-hua.yang@nyctcm.edu)[ ](dong-hua.yang@nyctcm.edu)Shaojie Wu [wshj510515@163.com](wshj510515@163.com)  \n1The Second Clinical Medical School, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China  \n2The First Affiliated Hospital of Soochow University, Suzhou 215006, China 3Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China  \n4New York College of Traditional Chinese Medicine, Mineola, NY 11501, USA  \n5Foresea Life Insurance Guangzhou General Hospital, Guangzhou 511300, China  \nBackground  \nCAR (chimeric antigen receptor)-T cell therapy is a cellbased treatment method in which T lymphocytes are genetically engineered to express antibodies with specificity for tumor-associated antigens [1]. By synthesizing corresponding antibodies, immune cells are directed to the location of tumor cells. This approach has demonstrated efficacy in treating relapsed/refractory B-cell leukemia and lymphoma, particularly in targeting CD19, which has proven effective in cases of acute lymphoblastic leukemia [2]. CAR-T cell therapy exhibits high specificity, potent cytotoxicity, and long-lasting efficacy and can control tumor progression in patients for whom conventional treatments have failed [3, 4]. Despite these benefits, numerous challenges persist. For example, tumor heterogeneity [5] and antigen escape [6, 7] lead to immune evasion and difficult-to-treat relapses. Moreover, the on-target off-tumor toxicity is a major limitation.  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from ","cbCainFjOdNazJIS","https://ap.wps.com/l/cbCainFjOdNazJIS","pdf",9180514,21,"English","# Background\n## TME composition and function\n## Immunosuppressive barriers affecting CAR-T performance","[{\"question\":\"Why are current CAR-T therapies less effective for solid tumors?\",\"answer\":\"Solid tumors often contain an immunosuppressive tumor microenvironment that limits CAR-T effectiveness and safety, reducing infiltration and function.\"},{\"question\":\"What strategies are suggested to improve CAR-T cell performance in tumors?\",\"answer\":\"The review emphasizes enhancing CAR-T infiltration and resolving immunosuppressive responses, including structural CAR-T alterations combined with targeted therapy, radiotherapy, or chemotherapy.\"},{\"question\":\"How does the tumor microenvironment contribute to CAR-T exhaustion?\",\"answer\":\"Physical and cytokine barriers, along with immunosuppressive molecules and cells, can create metabolic competition, depriving CAR-T cells of energy and promoting exhaustion.\"}]","Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy | PDF",1790016089,53]